A Thread Devoted To Gynecomastia

Discussion in 'Men's Health Forum' started by BBC3, Mar 26, 2011.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    US Jury Orders Johnson & Johnson To Pay $8bn To Man With Gynaecomastia Linked To Risperidone

    Johnson & Johnson and its subsidiary Janssen Pharmaceuticals have been ordered by a Philadelphia jury to pay $8bn (£6.5bn; €7.3bn) in punitive damages to Nicholas Murray, 26, who developed gynaecomastia while taking the atypical antipsychotic drug risperidone.

    Risperidone (marketed in the US by Janssen as Risperdal) can increase concentrations of the hormone prolactin, causing breast development in boys and men.

    Two different paediatricians prescribed the drug to Murray off label. He began taking it in 2003 when he was aged 9 for sleep disturbances associated with an autism spectrum disorder. He stopped five years later when the family became concerned about his developing breasts.

    In 2013, aged 20, Murray sued Janssen, alleging that the company downplayed the risk of gynecomastia in its marketing to doctors and its application …

    Dyer O. US jury orders Johnson & Johnson to pay $8bn to man with gynaecomastia linked to risperidone. BMJ (Clinical research ed) 2019;367:l5990. http://www.bmj.com/content/367/bmj.l5990.abstract
    Millard Baker likes this.
  2. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Gynaecomastia Caused by A Feminising Adrenal Tumour

    Gynaecomastia is a common finding which typically appears during puberty in boys and in elderly males. At these times, gynaecomastia is likely to be due to physiological hormonal fluctuations although there are a number of other causes including medications which must also be considered.

    We present a case of a 52 year old male with gynaecomastia, hypogonadotropic hypogonadism and hyperoestrogenaemia. MRI of the adrenals confirmed the presence of an adrenocortical carcinoma, which after pre-operative hormone workup was diagnosed as a feminising adrenal tumour. The lesion was excised and adjunct Mitotane therapy commenced.

    Hyperoestrogenaemia is often secondary to exogenous testosterone administration; however, in the presence of hypogonadotropic hypogonadism other sources of oestrogen should be sought.

    This case highlights a rare, but nonetheless important cause of gynaecomastia.

    Gibbons SM, Jassam N, Abbas A, Stuart K, Fairhurst A, Barth JH. ANNALS EXPRESS: Gynaecomastia caused by a feminising adrenal tumour. Annals of clinical biochemistry 2019:0004563219884960. SAGE Journals: Your gateway to world-class research journals
  3. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    [OA] Causes and Metabolic Consequences of gynecomastia

    Background: Gynecomastia (GM) is a benign enlargement of male breast due to glandular tissue proliferation. GM is a symptom of systemic or local hormonal disturbances, which could be associated with functional changes or pathological conditions. However, the long-lasting steroid imbalance in men with GM might exert negative influence on their metabolic health.

    Methods: A total of 110 adult men with symptomatic GM were included in the present retrospective cross-sectional study. Anthropometric, metabolic, and hormonal data of the patients were collected.

    Results: In almost 64% of GM patients, the underlying pathological condition was identified. Moreover, the development of GM was among the primary symptoms leading to the proper diagnosis in more than 40% of hypogonadal patients.

    The prevalence of metabolic syndrome (MS) was 53%; the highest prevalence of MS was found in patients with medication-induced GM and in the hypogonadal patients, whereas the lowest prevalence was observed in men with idiopathic postpubertal GM despite the similar degree of obesity. The lower testosterone levels were associated with more unfavorable lipid profile in the GM patients.

    Conclusion: The development of GM in adults might be an important symptom of an underlying gonadal disease. Moreover, it could be associated with an increased risk of metabolic disturbances.

    Our results support the need of detailed laboratory and hormonal investigations in patients with GM including targeted screening for metabolic disturbances.

    Further longitudinal studies are needed to evaluate the long-term consequences of sex hormones imbalance on cardiovascular morbidity and mortality in adults with GM.

    Robeva R, Elenkova A, Zacharieva S. Causes and Metabolic Consequences of Gynecomastia in Adult Patients. Int J Endocrinol 2019;2019:6718761. https://www.hindawi.com/journals/ije/2019/6718761/
  4. SaneDog

    SaneDog Member

    Cool thread, great read. There's a lot of information here.